Physician profile
Mark A Folts
NPI 1629068614
$11,093.36
in general payments reported to CMS, 2019-2025
24 companies · $3,798 in 2025
The $3,798 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $258 · 2022: $1,652 · 2023: $2,382 · 2024: $3,002 · 2025: $3,798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,968 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,968.14 |
| Education | $214.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,759.95 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $1,330.59 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,213.59 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,182.96 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,067.19 | 2022-2025 | |
| Lundbeck LLC | $933.10 | 2022-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $884.00 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $504.00 | 2022-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $364.13 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Corium, LLC | $354.11 | 2023-2025 | Azstarys |
| Axsome Therapeutics, INC. | $335.02 | 2023-2025 | Auvelity |
| Indivior INC. | $293.62 | 2022-2025 | Sublocade, Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $231.88 | 2022-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $188.35 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $90.53 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $82.84 | 2025 | Qelbree |
| Tempus Ai, INC | $58.22 | 2024 | |
| Braeburn INC. | $56.84 | 2024-2025 | Brixadi |
| Sunovion Pharmaceuticals INC. | $53.94 | 2022 | |
| Janssen Biotech, INC. | $31.40 | 2023-2025 | Invega Sustenna |
| Owp Pharmaceuticals, INC. | $24.95 | 2022 | |
| Si-Bone, INC. | $20.93 | 2021 | |
| Boston Scientific Corporation | $16.05 | 2021 | |
| Neuronetics, INC. | $15.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Folts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.